Research Analysts Set Expectations for VKTX Q1 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Viking Therapeutics in a research report issued to clients and investors on Thursday, February 6th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.26) for the quarter. HC Wainwright has a “Buy” rating and a $102.00 price target on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.51) EPS.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter last year, the business posted ($0.25) earnings per share.

Other research analysts also recently issued research reports about the stock. B. Riley reaffirmed a “buy” rating and issued a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a research report on Friday, February 7th. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. Citigroup began coverage on Viking Therapeutics in a research note on Friday, February 7th. They set a “neutral” rating and a $38.00 target price on the stock. Raymond James boosted their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a report on Thursday, February 6th. Finally, Maxim Group dropped their price target on Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $96.92.

Viking Therapeutics Price Performance

VKTX stock opened at $29.96 on Monday. Viking Therapeutics has a fifty-two week low of $29.08 and a fifty-two week high of $99.41. The business has a 50-day moving average of $39.22 and a 200-day moving average of $53.42. The stock has a market capitalization of $3.34 billion, a P/E ratio of -29.96 and a beta of 0.90.

Insiders Place Their Bets

In other Viking Therapeutics news, COO Marianna Mancini sold 54,215 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the completion of the transaction, the chief operating officer now owns 374,134 shares in the company, valued at approximately $15,994,228.50. This trade represents a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Greg Zante sold 50,309 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total transaction of $2,150,709.75. Following the completion of the transaction, the chief financial officer now owns 165,259 shares in the company, valued at approximately $7,064,822.25. The trade was a 23.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 299,014 shares of company stock valued at $12,782,849 in the last 90 days. Corporate insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On Viking Therapeutics

Several institutional investors have recently made changes to their positions in VKTX. Oak Ridge Investments LLC acquired a new position in Viking Therapeutics during the 3rd quarter valued at about $837,000. Oppenheimer & Co. Inc. boosted its position in shares of Viking Therapeutics by 43.5% during the third quarter. Oppenheimer & Co. Inc. now owns 102,324 shares of the biotechnology company’s stock valued at $6,478,000 after buying an additional 31,011 shares during the last quarter. Nvwm LLC bought a new stake in Viking Therapeutics during the third quarter worth $999,000. Chartwell Investment Partners LLC raised its position in Viking Therapeutics by 88.0% in the 3rd quarter. Chartwell Investment Partners LLC now owns 36,666 shares of the biotechnology company’s stock valued at $2,322,000 after buying an additional 17,159 shares during the last quarter. Finally, Stifel Financial Corp raised its position in Viking Therapeutics by 92.1% in the 3rd quarter. Stifel Financial Corp now owns 131,348 shares of the biotechnology company’s stock valued at $8,316,000 after buying an additional 62,956 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.